Spero Therapeutics. has been granted a patent for a tebipenem pivoxil HBr tablet formulation, comprising at least 70% tebipenem pivoxil HBr, along with specific percentages of diluents, glidants, lubricants, and disintegrants. The formulation is intended for treating various bacterial infections, including complicated urinary tract infections. GlobalData’s report on Spero Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Spero Therapeutics, Anti-bacterial thiazole derivatives was a key innovation area identified from patents. Spero Therapeutics's grant share as of July 2024 was 46%. Grant share is based on the ratio of number of grants to total number of patents.
Tebipenem pivoxil hbr tablet formulation for bacterial infections
The granted patent US12048691B2 outlines a formulation for a tebipenem pivoxil HBr tablet core, which comprises a minimum of 70% w/w tebipenem pivoxil HBr, along with specific percentages of other excipients. These include 15-25% w/w microcrystalline cellulose as a binder/diluent, 0.5-2% w/w crospovidone as a disintegrant, 0.5-2% w/w silicon dioxide as a glidant, and 0.5-2% w/w magnesium stearate. The patent further specifies variations in the formulation, such as the use of microcrystalline cellulose grade PH-101, crospovidone XL-10, and colloidal silicon dioxide grade 200. The tablet core is designed to achieve over 90% dissolution in less than five minutes in a specified buffered medium, indicating a rapid release profile.
Additionally, the patent describes methods for treating bacterial infections, including urinary tract infections and nontuberculous mycobacterial infections, using the tebipenem pivoxil HBr tablet. The tablet is noted to contain 300 mg of tebipenem pivoxil and is coated with an immediate release coating, which can be an aqueous film coating. The claims also detail specific treatment regimens for various infections, including complicated urinary tract infections and infections caused by resistant strains of E. coli. The formulation is further characterized by the presence of tebipenem pivoxil crystalline Form B, with claims specifying the proportions of the active ingredient and excipients in the tablet core. Overall, the patent provides a comprehensive framework for the composition and therapeutic applications of tebipenem pivoxil HBr tablets.
To know more about GlobalData’s detailed insights on Spero Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
